- Home
- LANV vs ATYR Comparison
LANV vs ATYR Comparison
Compare LANV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LANV
- ATYR
- Stock Information
- Founded
- LANV 2015
- ATYR 2005
- Country
- LANV China
- ATYR United States
- Employees
- LANV N/A
- ATYR N/A
- Industry
- LANV Blank Checks
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LANV Finance
- ATYR Health Care
- Exchange
- LANV Nasdaq
- ATYR Nasdaq
- Market Cap
- LANV 258.1M
- ATYR 306.2M
- IPO Year
- LANV N/A
- ATYR 2015
- Fundamental
- Price
- LANV $2.07
- ATYR $5.22
- Analyst Decision
- LANV
- ATYR Strong Buy
- Analyst Count
- LANV 0
- ATYR 6
- Target Price
- LANV N/A
- ATYR $18.60
- AVG Volume (30 Days)
- LANV 36.4K
- ATYR 2.3M
- Earning Date
- LANV 04-30-2025
- ATYR 05-07-2025
- Dividend Yield
- LANV N/A
- ATYR N/A
- EPS Growth
- LANV N/A
- ATYR N/A
- EPS
- LANV N/A
- ATYR N/A
- Revenue
- LANV $340,211,202.00
- ATYR N/A
- Revenue This Year
- LANV $11.74
- ATYR $1,093.62
- Revenue Next Year
- LANV $11.11
- ATYR $1,129.59
- P/E Ratio
- LANV N/A
- ATYR N/A
- Revenue Growth
- LANV N/A
- ATYR N/A
- 52 Week Low
- LANV $0.91
- ATYR $1.42
- 52 Week High
- LANV $2.69
- ATYR $5.98
- Technical
- Relative Strength Index (RSI)
- LANV 44.29
- ATYR 70.19
- Support Level
- LANV $2.02
- ATYR $5.25
- Resistance Level
- LANV $2.18
- ATYR $5.98
- Average True Range (ATR)
- LANV 0.12
- ATYR 0.43
- MACD
- LANV -0.02
- ATYR 0.05
- Stochastic Oscillator
- LANV 26.13
- ATYR 69.33
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.